People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aadi Bioscience, Inc. | — | Biotechnology | Series D+ | $451.8M | $878.4M | 2021 |
| Cardurion Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $431.7M | $2.8B | 2024 |
| Ribon Therapeutics, Inc. | — | Biotechnology | Series B | $119.1M | $342.8M | 2022 |
| ReAlta Life Sciences, Inc. | — | Biotechnology | Series B | $108.3M | $145.9M | 2023 |
Emma Reeve at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Emma Reeve on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jonathan Root | 1 | 16 |
| Edward Mathers | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Cameron Wheeler | 1 | 9 |
| Andrew Miller | 1 | 8 |
| Daniel Lynch | 1 | 7 |
| Jeff Goater | 1 | 4 |
| Paul Brannelly | 1 | 4 |
| Paul M. Weiss | 1 | 4 |
| Keith Gottesdiener | 1 | 4 |
| Adam Koppel | 1 | 3 |
| Kenneth Novack | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Eyal Lifschitz | 1 | 3 |
| Peter Lawrence | 1 | 3 |
| John Harding | 1 | 3 |
| LAURA BRASS | 1 | 3 |
| Neil Desai | 1 | 3 |
| Caley Castelein | 1 | 2 |
| Steven M. Prelack | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.